semaglutide approval mash FDA Expands Novo Nordisk's Wegovy to the Fatty Liver Disease Exciting Phase 3 Data from

In a randomized, double-blind, placebo-controlled human trial, chronic supplementation with the NAD+ precursor nicotinamide riboside was well tolerated and effectively raised NAD+ metabolism in healthy middle-aged and older adults, with early signals toward lower blood pressure and arterial stiffness[1]

As it stands, evidence to inform clinical management and public health policy is lacking and observational studies have been proven to be challenging to undertake and extrapolate into this arena

Despite the recent Wegovy approval, theres already a new drug on the block, which seemingly packs even more punch

A modification of the ABTS decolorization method and an insight into its mechanism